Literature DB >> 1884721

Long-term amiodarone therapy raises serum cholesterol.

A A Lakhdar1, E Farish, W S Hillis, F G Dunn.   

Abstract

Serum total cholesterol and triglyceride levels were measured in 12 patients before and 3.6 and 9 months after treatment with amiodarone. In addition, we monitored serum T4, T3, reverse T3 and TSH levels. Amiodarone and its desethyl metabolite levels were measured on each occasion. Serum total cholesterol and T4 levels rose from 5.95 mmol/l, and 102.7 mmol/l respectively at baseline to 6.95 and 115.8 at 6 months and reverse T3 increased at 3, 6 and 9 months from baseline. Serum triglycerides did not change. No relationship existed between cholesterol, T4 and T3 and amiodarone (or its metabolite) levels nor between cholesterol and thyroid hormone levels. These data demonstrate that amiodarone therapy is associated with an elevation in serum cholesterol. This may have clinical implications in view of the current widespread use of the drug.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1884721     DOI: 10.1007/bf00315226

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  Elevation of serum total cholesterol and triglyceride levels during amiodarone therapy.

Authors:  P T Pollak; A D Sharma; S G Carruthers
Journal:  Am J Cardiol       Date:  1988-09-15       Impact factor: 2.778

2.  Quantitative determination of serum triglycerides by the use of enzymes.

Authors:  G Bucolo; H David
Journal:  Clin Chem       Date:  1973-05       Impact factor: 8.327

3.  Interrelationships between serum levels of amiodarone, desethylamiodarone, reverse T3 and the QT interval during long-term amiodarone treatment.

Authors:  J M Baerman; T Annesley; L A DiCarlo; M K Foley; J M Nicklas; B J Crevey; F Morady
Journal:  Am Heart J       Date:  1986-04       Impact factor: 4.749

4.  Can amiodarone induce hyperglycaemia and hypertriglyceridaemia?

Authors:  A Politi; G Poggio; A Margiotta
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-28

5.  Frequent neurologic toxicity associated with amiodarone therapy.

Authors:  M E Charness; F Morady; M M Scheinman
Journal:  Neurology       Date:  1984-05       Impact factor: 9.910

6.  Amiodarone and thyroid hormone action.

Authors:  J A Franklyn; J R Davis; M D Gammage; W A Littler; D B Ramsden; M C Sheppard
Journal:  Clin Endocrinol (Oxf)       Date:  1985-03       Impact factor: 3.478

7.  Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyrotropin. A drug influencing peripheral metabolism of thyroid hormones.

Authors:  A Burger; D Dinichert; P Nicod; M Jenny; T Lemarchand-Béraud; M B Vallotton
Journal:  J Clin Invest       Date:  1976-08       Impact factor: 14.808

8.  Acute necrotizing pneumonitis and hyperglycemia after amiodarone therapy. Case report and review of amiodarone-associated pulmonary disease.

Authors:  P T Pollak; M Sami
Journal:  Am J Med       Date:  1984-05       Impact factor: 4.965

9.  Amiodarone and thyroid function: clinical implications during antiarrhythmic therapy.

Authors:  B N Singh; K Nademanee
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

10.  Role of phospholipase A inhibition in amiodarone pulmonary toxicity in rats.

Authors:  K Y Hostetler; M J Reasor; E R Walker; P J Yazaki; B W Frazee
Journal:  Biochim Biophys Acta       Date:  1986-02-12
View more
  1 in total

1.  The 3D OrbiSIMS-label-free metabolic imaging with subcellular lateral resolution and high mass-resolving power.

Authors:  Melissa K Passarelli; Alexander Pirkl; Rudolf Moellers; Dmitry Grinfeld; Felix Kollmer; Rasmus Havelund; Carla F Newman; Peter S Marshall; Henrik Arlinghaus; Morgan R Alexander; Andy West; Stevan Horning; Ewald Niehuis; Alexander Makarov; Colin T Dollery; Ian S Gilmore
Journal:  Nat Methods       Date:  2017-11-13       Impact factor: 28.547

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.